Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | OXTR | P30559 | 6/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166752 | 0.84 | MAPT (0.50) | MAPTGAAOXTRAVPR1AMEN1 | |
| SCHEMBL1337005 | 0.84 | NPC1 (0.59) | GAAOXTRAVPR1AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1336911 | 0.83 | NPC1 (0.58) | GAAOXTRAVPR1AMEN1KMT2A | |
| SCHEMBL16059596 | 0.74 | NPC1 (0.59) | MAPTGAAOXTRAVPR1AMEN1 | |
| SCHEMBL334445 | 0.73 | MEN1 (0.50) | MAPTOXTRAVPR1AMEN1KMT2A | |
| SCHEMBL334420 | 0.73 | PTGES (0.51) | MAPTGAAMEN1KMT2APOLB | |
| SCHEMBL25379372 | 0.73 | OXTR (0.54) | GAAOXTRAVPR1AMEN1KMT2A | |
| SCHEMBL14640493 | 0.73 | POLB (0.53) | MAPTGAAOXTRAVPR1AMEN1 | |
| SCHEMBL63670 | 0.72 | KMT2A (0.64) | MAPTGAAOXTRAVPR1AMEN1 | |
| SCHEMBL20776699 | 0.72 | OXTR (0.53) | OXTRAVPR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904504-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2014-03-19 | — | — | EP | disclosed |
| EP-1781664-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MAPT 2430/4885GAA 1146/4885OXTR 1000/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | MAPT 2430/4885GAA 1146/4885OXTR 1000/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | MAPT 2430/4885GAA 1146/4885OXTR 1000/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | MAPT 2320/4885GAA 1197/4885OXTR 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.